• Poster 504: BMS-232632: A Summary of Multiple Dose Pharmacokinetic, Food Effect and Drug Interaction Studies in Healthy Subjects (Authored E. O'mara, V. Mummaneni, D. Randall, N. Sagali, S. Olsen, T. Tanner, A. Schuster, R. Raymond, and S. Kau. Bristol-Myers Squibb Pharmaceutical Res. Inst., Princeton, NJ and Simbec Res., Ltd., Merthyr Tydfil, UK)
  Click here to view the original abstract

The protease inhibitor BMS-232632 is a promising investigational drug under development by Bristol-Myers Squibb. In these pharmocokinetic studies done in healthy, HIV-negative subjects, the following important points were presented:

• The drug was well-tolerated at doses ranging from 200 mg to 800 mg daily for 14 days.

• At the 400 mg daily dose, the levels of the drug exceeded the IC90 of the virus for 24 hours, allowing once-daily dosing.

• Taking the medication with food increases drug exposure.

• Co-administration of BMS-232632 with ddI/d4T reduces its absorption; this effect is eliminated if the protease inhibitor is given one hour after d4T/ddI.

• When given with saquinavir, BMS-232632 and saquinavir can both be given once-daily.

BMS-232632 is currently in phase I/II clinical trials.